{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:10:48Z","timestamp":1784243448112,"version":"3.55.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ertapenem-induced neurotoxicity has not been well characterized and is potentially underreported. We conducted a systematic review of the literature and included 11 additional cases from the University of Washington Medicine health system. A total of 125 individual patient cases were included in the data analysis. The mean age was 72 years, and 62% and 42% of patients had renal dysfunction and preexisting central nervous system (CNS) conditions, respectively. Only 15% of patients received inappropriately high ertapenem dosing based on kidney function. Patients developed neurological signs and symptoms after a median of 4 days (interquartile range, 3\u20139 days). The most common clinical features were seizures (70%), altered level of consciousness or delirium (27%), and hallucinations (17%). An estimated incidence in our health system was 1 in 102 courses of ertapenem. Ertapenem neurotoxicity should be suspected when a patient with renal dysfunction or predisposing CNS conditions develops neurological signs and symptoms, especially within several days after initiating the antibiotic. This study underscores the need for a large prospective study to assess the true incidence and outcomes of ertapenem neurotoxicity.<\/jats:p>","DOI":"10.1093\/ofid\/ofae214","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T19:49:18Z","timestamp":1713296958000},"source":"Crossref","is-referenced-by-count":5,"title":["Characterizing Ertapenem Neurotoxicity: A Systematic Review and Experience at a Tertiary Medical Center"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0765-3955","authenticated-orcid":false,"given":"Hayato","family":"Mitaka","sequence":"first","affiliation":[{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-270X","authenticated-orcid":false,"given":"Shinya","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine F","family":"Lan","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-6775","authenticated-orcid":false,"given":"Rupali","family":"Jain","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington , Seattle, Washington , USA"},{"name":"School of Pharmacy, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Rakita","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9143-8857","authenticated-orcid":false,"given":"Paul S","family":"Pottinger","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"2024053113375770200_ofae214-B1","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/jac\/dkv502","article-title":"Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study","volume":"71","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2024053113375770200_ofae214-B2","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1128\/AAC.05913-11","article-title":"Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"56","author":"Collins","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024053113375770200_ofae214-B3","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/cid\/ciz173","article-title":"A primer on AmpC \u03b2-lactamases: necessary knowledge for an increasingly multidrug-resistant world","volume":"69","author":"Tamma","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024053113375770200_ofae214-B4","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/jac\/dkq152","article-title":"Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing gram-negative organisms","volume":"65","author":"Bazaz","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2024053113375770200_ofae214-B5","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.02721-14","article-title":"Safety and efficacy of long-term outpatient ertapenem therapy","volume":"58","author":"Qureshi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024053113375770200_ofae214-B6","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/microorganisms9071505","article-title":"Beta-lactams toxicity in the intensive care unit: an underestimated collateral damage?","volume":"9","author":"Roger","year":"2021","journal-title":"Microorganisms"},{"key":"2024053113375770200_ofae214-B7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40801-021-00268-1","article-title":"Delirium associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Teng","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"2024053113375770200_ofae214-B8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"2024053113375770200_ofae214-B9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2024053113375770200_ofae214-B10","doi-asserted-by":"crossref","first-page":"ofx170","DOI":"10.1093\/ofid\/ofx170","article-title":"Characterizing cefepime neurotoxicity: a systematic review","volume":"4","author":"Appa","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2024053113375770200_ofae214-B11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care"},{"key":"2024053113375770200_ofae214-B12","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1093\/jac\/dkac271","article-title":"Cefepime-induced neurotoxicity: systematic review","volume":"77","author":"Maan","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024053113375770200_ofae214-B13","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/WNL.0000000000002023","article-title":"Seizures as adverse events of antibiotic drugs: a systematic review","volume":"85","author":"Sutter","year":"2015","journal-title":"Neurology"},{"issue":"Suppl 2","key":"2024053113375770200_ofae214-B14","first-page":"ii23","article-title":"Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians","volume":"53","author":"Nix","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2024053113375770200_ofae214-B15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/ciad558","article-title":"Considerations and concerns regarding the use of ertapenem in patients with hypoalbuminemia: is it truly inappropriate?","volume":"78","author":"Phinder-Puente","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2024053113375770200_ofae214-B16","doi-asserted-by":"crossref","first-page":"e0182046","DOI":"10.1371\/journal.pone.0182046","article-title":"Risk factors associated with the development of seizures among adult patients treated with ertapenem: a matched case-control study","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"2024053113375770200_ofae214-B17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/1060028020938059","article-title":"Ertapenem neurotoxicity in hemodialysis patients\u2014safe and effective dosing is still needed: a retrospective study and literature review","volume":"55","author":"El Nekidy","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2024053113375770200_ofae214-B18","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/jac\/dku111","article-title":"The risk of seizures among the carbapenems: a meta-analysis","volume":"69","author":"Cannon","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2024053113375770200_ofae214-B19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/1120009X.2016.1158937","article-title":"Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections","volume":"29","author":"Trad","year":"2017","journal-title":"J Chemother"},{"key":"2024053113375770200_ofae214-B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy867","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae214\/57245123\/ofae214.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/5\/ofae214\/57977979\/ofae214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/5\/ofae214\/57977979\/ofae214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T21:47:01Z","timestamp":1717192021000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae214\/7646757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae214","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,4,16]]},"article-number":"ofae214"}}